LNCD(SH:600739)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥3,090,395,487.29, representing a decrease of 25.06% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥101,537,387.84, down 58.85% year-over-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥115,345,087.10, a decrease of 43.55% compared to the previous year[4]. - The basic earnings per share for Q3 2023 was ¥0.0667, reflecting a decline of 58.73% year-over-year[4]. - The diluted earnings per share for Q3 2023 was also ¥0.0667, down 58.73% compared to the same period last year[4]. - The weighted average return on equity for Q3 2023 was 0.35%, a decrease of 0.51 percentage points year-over-year[4]. - The total operating revenue for the year-to-date period was ¥7,770,813,276.53, down 34.95% year-over-year[4]. - The net profit attributable to shareholders for the year-to-date period was ¥598,129,400.23, reflecting a decrease of 49.53% compared to the same period last year[4]. - The total comprehensive income for the period was ¥1,241,791,454.00, up from ¥1,040,999,109.07, reflecting a growth of approximately 19.3%[42]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was -¥106,070,381.40, a decline of 110.01% compared to the previous year[4]. - The net cash flow from operating activities was negative at -¥503,702,500.15, a significant decline from ¥882,736,562.72 in the previous year[43]. - Cash inflow from investment activities totaled ¥905,822,224.28, slightly down from ¥945,833,599.26 year-over-year[43]. - The net cash flow from investment activities was -1,324,194,311.78 RMB, contrasting with a positive cash flow of 2,170,743,554.55 RMB in the same period last year[57]. - Cash inflow from investment activities decreased to 4,231,489,255.57 RMB, down 37.5% from 6,783,612,813.98 RMB year-over-year[57]. Assets and Liabilities - Total assets at the end of the reporting period were ¥46,749,782,257.18, a decrease of 2.90% compared to the previous year-end[17]. - Total liabilities amounted to ¥14,492,927,165.68, down from ¥15,920,151,988.78 year-over-year[21]. - Total current assets decreased to ¥10,920,675,155.55 from ¥13,404,445,003.22, a decline of approximately 18.5% year-over-year[49]. - Total assets decreased to ¥46,749,782,257.18 from ¥48,148,446,487.04, a decline of approximately 2.8%[50]. - Total liabilities increased to ¥15,920,151,988.78 from ¥15,924,268,058.32, a slight decrease of about 0.03%[47]. Shareholder Information - The number of common shareholders at the end of the reporting period was 66,322[19]. - The largest shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., holds 15.30% of shares, with 234,004,700 shares pledged[19]. - Equity attributable to shareholders of the listed company increased to ¥29,156,728,141.77, reflecting a growth of 1.56% year-over-year[17]. Operational Insights - The decline in revenue and profit was primarily due to a decrease in the scale of medical material exports and increased losses in energy development[8]. - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[18]. - The company reported a government subsidy income of ¥7,261,602.17 during the current period[17]. Cost Management - Total operating costs for the period were CNY 7,744,446,343.29, a decrease from CNY 11,219,835,111.15 in the previous period[23]. - Financial expenses decreased to CNY 250,662,306.13, down 11.3% from CNY 282,454,360.04 in the previous year[61]. Future Outlook - The company plans to implement new accounting standards starting from 2023, which may affect the financial statements[44].